Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Holliston, MA, Dec. 04, 2023 (GLOBE NEWSWIRE) — Harvard Apparatus Regenerative Technology, Inc. (OTCQB:HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced that it officially executed a Sponsored Research Agreement (SRA) with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.
Related news for (HRGN)
- Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
- Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results